Get the Stockscreener App
17.76
0.95%
-0.1587
Keros Therapeutics Inc stock is traded at $17.76, with a volume of 310.58K.
It is down -0.95% in the last 24 hours and down -18.17% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$17.92
Open:
$18.1
24h Volume:
310.58K
Relative Volume:
0.31
Market Cap:
$541.08M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-3.4622
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
-12.43%
1M Performance:
-18.17%
6M Performance:
+31.97%
1Y Performance:
+13.49%
1-Day Range:
$17.51
$18.10
1-Week Range:
$17.51
$20.49
52-Week Range:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
17.76 | 545.95M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.16 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.22 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.06 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
802.27 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.79 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
What analysts say about Keros Therapeutics Inc stockSector Rotation Strategies & Real-Life Case Studies You Can Follow - earlytimes.in
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.3% on Analyst Downgrade - Defense World
Keros Therapeutics (NASDAQ:KROS) Cut to “Hold” at Zacks Research - Defense World
(KROS) Risk Channels and Responsive Allocation - Stock Traders Daily
Keros Therapeutics (NASDAQ:KROS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3%Time to Sell? - MarketBeat
Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics - Yahoo Finance
Short Interest in Keros Therapeutics, Inc. (NASDAQ:KROS) Drops By 16.6% - MarketBeat
5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close - Yahoo Finance
KROS or ARGX: Which Is the Better Value Stock Right Now? - sharewise.com
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - Quantisnow
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Keros Therapeutics Reports Strong Revenue Growth - MSN
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Assenagon Asset Management S.A. Has $4.07 Million Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Keros Therapeutics (NASDAQ:KROS) Raised to “Hold” at TD Cowen - Defense World
Keros Therapeutics (NASDAQ:KROS) Upgraded at TD Cowen - MarketBeat
Can Keros Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
How rising interest rates impact Keros Therapeutics Inc. stockJuly 2025 Snapshot & Long-Term Capital Growth Ideas - DonanımHaber
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.7%Here's Why - MarketBeat
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 - The Globe and Mail
Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros - sharewise.com
Keros Therapeutics Earnings Notes - Trefis
TFG Asset Management GP Ltd Sells 55,000 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics commences tender offer to repurchase up to $194.4 million shares - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - sharewise.com
KROS vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Stocks showing market leadership: Keros Therapeutics earns 92 RS rating - MSN
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc. - MarketBeat
Aug Summary: How Keros Therapeutics Inc stock performs in interest rate cyclesWeekly Trade Report & Daily Profit Focused Screening - moha.gov.vn
Myelofibrosis Market to Expand Significantly by 2034, States DelveInsight Report | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Stocks to watch: Keros Therapeutics sees relative strength rating rise to 82 - MSN
Would You Still Hold Keros Therapeutics Stock If It Fell 30%? - Trefis
Can Keros Therapeutics Stock Hold Up When Markets Turn? - Trefis
Keros Therapeutics (NASDAQ:KROS) Trading Up 12%Here's Why - MarketBeat
There's No Escaping Keros Therapeutics, Inc.'s (NASDAQ:KROS) Muted Revenues Despite A 30% Share Price Rise - 富途牛牛
How Keros Therapeutics Inc. stock benefits from tech adoptionWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - Newser
Franklin Resources Inc. Grows Stake in Keros Therapeutics, Inc. $KROS - Defense World
Will Keros Therapeutics Inc. stock outperform growth indexesBull Run & Fast Momentum Entry Tips - Newser
Top investors say Keros Therapeutics Inc (KROS) ticks everything they need - setenews.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities - The Globe and Mail
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00 - MarketBeat
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
5,389,264 |
95,659,436 |
0 |
2.45%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):